Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-25
    E.g., 2018-02-25


49993 items
3:12 PM, Feb 21, 2018  |  BC Extra | Clinical News

Mesoblast's MSCs meet in Phase III for acute GvHD

Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said remestemcel-L (MSC-100-IV) met the primary endpoint in a Phase III trial to treat steroid-refractory acute graft-versus-host disease (GvHD). The company said full data from the trial, which are expected next...
2:48 PM, Feb 21, 2018  |  BC Extra | Politics & Policy

Australia legislates lower drug prices

The Australian government passed legislation that mandates steeper price cuts to drugs on the country's Pharmaceutical Benefits Scheme (PBS). The law increases the statutory price reduction applied to a drug upon approval of the first...
2:22 PM, Feb 21, 2018  |  BC Extra | Company News

Merck buying oncolytic virus play Viralytics for $398M

Merck & Co. Inc. (NYSE:MRK) will acquire oncolytic immunotherapy company Viralytics Ltd. (ASX:VLA; OTCQX:VRACY) for A$1.75 per share, or A$502 million ($398 million). The price is a 182% premium to Viralytics’ close of A$0.62 on...
1:51 PM, Feb 21, 2018  |  BC Extra | Financial News

Oric raises $50M series C

Oric Pharmaceuticals Inc. (South San Francisco, Calif.) raised $50 million in a series C round from new investors Fidelity Management & Research, Trinitas Capital, Taiho Ventures and NS Investment. Existing investors, including The Column Group,...
1:28 PM, Feb 21, 2018  |  BC Extra | Company News

Former OncoMed CEO Hastings joins Nkarta

Nkarta Inc. (South San Francisco, Calif.) hired Paul Hastings as president and CEO. Last month, Hastings resigned as chairman, president and CEO of cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) (see BioCentury Extra, Jan. 9). Founded in...
12:45 PM, Feb 21, 2018  |  BC Extra | Politics & Policy

India names new drugs controller general

The Government of India's Ministry of Health and Family Welfare appointed S. Eswara Reddy as drugs controller general of India for three months, or until a permanent appointment is found. Reddy, who was joint drug...
12:06 PM, Feb 21, 2018  |  BC Extra | Clinical News

AbbVie's elagolix meets in Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-I (M12-815) trial to treat uterine fibroids. The trial is the first of two replicate Phase...
4:15 PM, Feb 20, 2018  |  BC Extra | Company News

Takeda, Wave in CNS nucleic acid deal

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Wave Life Sciences Ltd. (NASDAQ:WVE) partnered to develop and commercialize nucleic acid therapies to treat CNS diseases. Wave will receive an upfront payment of $170 million, including $110 million in...
4:06 PM, Feb 20, 2018  |  BC Extra | Clinical News

Eli Lilly stops Phase II trial of BTK inhibitor in RA

Eli Lilly and Co. (NYSE:LLY) discontinued the Phase II RAjuvenate trial of HM71224 (LY3337641) to treat rheumatoid arthritis after a planned analysis showed that the difference between the active and placebo control arms "was not...
3:57 PM, Feb 20, 2018  |  BC Extra | Company News

JNJ execs launch Centyrins newco Aro

Two former Johnson & Johnson (NYSE:JNJ) executives have co-founded Aro Biotherapeutics Co. (Philadelphia, Pa.) to develop Centyrins for extra-hepatic, receptor-mediated delivery of oligonucleotides and other payloads. Aro President and CEO Susan Dillon was previously global...